ID | 110046 |
Title Alternative | 局所進行膵癌に対するゲムシタビン定速静注及びS-1併用化学放射線療法の第Ⅰ/Ⅱ相試験
FDR-gem plus S-1 with RT for pancreatic cancer
|
Author |
Miyamoto, Hiroshi
University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Kagemoto, Kaizo
University of Tokushima
Okazaki, Jun
University of Tokushima
Takaoka, Yoshifumi
University of Tokushima
Miyamoto, Yoshihiko
University of Tokushima
Matsumoto, Sayo
University of Tokushima
Sueuchi, Tatsuhisa
University of Tokushima
Tanaka, Kumiko
University of Tokushima
Takaoka, Toshi
University of Tokushima
Okamoto, Koichi
University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Kimura, Masako
University of Tokushima
Sogabe, Masahiro
University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Muguruma, Naoki
University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Okahisa, Toshiya
University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Sato, Yasuhiro
Hokkaido Cancer Center
Sagawa, Tamotsu
Hokkaido Cancer Center
Fujikawa, Koji
Hokkaido Cancer Center
Ikushima, Hitoshi
University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Takayama, Tetsuji
University of Tokushima
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
|
Keywords | Pancreatic cancer
Chemoradiotherapy
Fixed-dose-rate gemcitabine
S-1
gemcitabine
radiosensitizer
|
Content Type |
Thesis or Dissertation
|
Description | Purpose: This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data.
Methods: Patients with unresectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400mg/m2, 5mg/m2/min) on days 1, 8, 22, 29 and 60mg/m2 of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28fractions) was delivered concurrently. Results: Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300mg/m2 of gemcitabine and 60mg/m2 of S-1 daily. The overall response rate was 25% and disease control rate (partial response plus stable disease) was 92%. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rate were 16.0 months and 73%, respectively. Conclusion: The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC. |
Journal Title |
Cancer Chemotherapy and Pharmacology
|
ISSN | 03445704
14320843
|
NCID | AA00598397
AA1161885X
|
Publisher | Springer nature
|
Volume | 76
|
Issue | 3
|
Start Page | 615
|
End Page | 620
|
Published Date | 2015-07-29
|
Remark | 内容要旨・審査要旨・論文本文の公開:
内容要旨・審査要旨:LID201704141008.pdf 論文本文:k3028_fulltext.pdf 本論文は, 著者Takahiro Gojiの学位論文として提出され, 学位審査・授与の対象となっている。 The final publication is available at link.springer.com. |
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
ETD
|
MEXT report number | 甲第3028号
|
Diploma Number | 甲医第1332号
|
Granted Date | 2017-03-23
|
Degree Name |
Doctor of Medical Science
|
Grantor |
Tokushima University
|
departments |
University Hospital
Medical Sciences
|